| Price | 10.20p on 10-12-2025 at 19:40:09 |
|---|---|
| Change | -0.05p -0.49% |
| Buy | 10.40p |
| Sell | 10.00p |
| Last Trade: | Buy 228,430.00 at 10.3292p |
| Day's Volume: | 5,494,454 |
| Last Close: | 10.20p |
| Open: | 10.25p |
| ISIN: | GB00BYV81293 |
| Day's Range | 9.56p - 10.20p |
| 52wk Range: | 2.20p - 12.35p |
| Market Capitalisation: | £108.30m |
| VWAP: | 9.780765p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 228,430 | 10.3292p | Ordinary |
16:22:13 - 10-Dec-25 |
| Sell* | 84,431 | 10.11p | Ordinary |
16:21:47 - 10-Dec-25 |
| Buy* | 5,000 | 10.356p | Ordinary |
16:15:29 - 10-Dec-25 |
| Sell* | 100,000 | 10.10p | Ordinary |
16:03:58 - 10-Dec-25 |
| Buy* | 116,099 | 10.336p | Ordinary |
15:36:28 - 10-Dec-25 |
| Buy* | 78 | 10.40p | SI Trade |
15:08:38 - 10-Dec-25 |
| Buy* | 100,000 | 10.25p | Ordinary |
15:07:54 - 10-Dec-25 |
| Sell* | 900 | 10.0028p | Ordinary |
15:04:46 - 10-Dec-25 |
| Buy* | 35 | 10.40p | SI Trade |
15:04:45 - 10-Dec-25 |
| Sell* | 80 | 9.90p | SI Trade |
15:04:45 - 10-Dec-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 3rd Dec 2025 7:04 am | RNS | Amends Senior Secured Debt Financing |
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |
| 15th Sep 2025 7:00 am | RNS | £1.5 million placing supporting growth of ACCRUFeR |
| 4th Sep 2025 7:03 am | RNS | ACCRUFeR® assigned Priority Review in US by FDA |
